For US Residents and Healthcare Professionals only.

Pemgarda (pemivibart) injection for intravenous use

PEMGARDA™ AUTHORIZED FOR EMERGENCY USE

Infusion Center Locator

Search for infusion centers near you by entering your city or ZIP Code or click the link below to request inclusion of your facility.

Pemgarda Logo

PEMGARDA™ Infusion Sites of Care:
Sites of care that have experience administering PEMGARDA and/or are available to receive PEMGARDA referrals from your healthcare provider.

Number of active sites
642

      Request to add, modify, or remove your facility

      NOTICE TO ALL: Invivyd, Inc. (Invivyd) does not own or operate any infusion sites. The Invivyd Infusion Center Locator Directory (“Locator”) is a public resource for informational purposes only and the sites displayed are not continuously vetted. The Locator is to be used by website visitors for the purpose of helping identify appropriate sites of care. It is intended solely for personal and non-commercial use to locate infusion site locations; any other use is strictly prohibited. This Locator includes infusion service providers compiled by Invivyd that have expressed interest in being listed on the Locator or who are known to have experience with Invivyd products. The results shown may not include all infusion sites that may have experience with Invivyd products in your area. Invivyd does not guarantee the accuracy or completeness of any information provided herein. Website visitors should contact infusion sites directly with all medication, insurance coverage, facility, and other site-specific inquiries. No fees or other remuneration have been or will be exchanged for an infusion site’s inclusion in this database. Unless otherwise stated, Invivyd is not affiliated with any of the listed infusion sites, and inclusion in this list does not represent an endorsement of or referral to the infusion sites contained in this database, nor does it represent an endorsement of Invivyd products by any infusion site listed. 

      NOTICE TO HEALTHCARE PROVIDERS: Healthcare providers are responsible for compliance with state and federal laws regulating physician referrals, including state professional practice restrictions. Invivyd hereby disclaims any liability arising from your use of and/or reliance on the information contained in this Locator. If you are a healthcare provider whose practice is currently being shown on the Locator and you would like to opt out or update your information, please send Invivyd a request by clicking “Request to add, modify, or remove your facility” underneath the map graphic. Invivyd is not liable for the accuracy of the information in an infusion site’s profile.  

      NOTICE TO PATIENTS: Invivyd is not a healthcare provider. It does not render medical advice or services. Please contact your physician, other healthcare provider, or the infusion site directly with all medication, referral, facility, and otherwise medical and site-specific questions. This Locator is not intended for children under the age of eighteen (18) years. Invivyd will not knowingly collect information from visitors under the age of eighteen (18) years. 

      Important Safety Information Expand

      WARNING: ANAPHYLAXIS

      • Anaphylaxis has been observed with PEMGARDA in 0.6% (4/623) of participants in a clinical trial.
      • Anaphylaxis was reported during the first and second infusion of PEMGARDA.
      • Anaphylaxis can be life-threatening.
      • Prior to administering PEMGARDA, consider the potential benefit of COVID-19 prevention along with the risk of anaphylaxis.
      • Administer PEMGARDA only in settings in which healthcare providers have immediate access to medications to treat anaphylaxis and the ability to activate the emergency medical system (EMS), as necessary.
      • Clinically monitor individuals during the infusion and for at least two hours after completion of the infusion.
      • Discontinue PEMGARDA use permanently if signs or symptoms of anaphylaxis or any severe systemic reaction are observed and initiate appropriate medications and/or supportive therapy.

      EMERGENCY USE AUTHORIZATION (EUA) FOR PEMGARDA

      The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA for the pre-exposure prophylaxis of COVID-19 in adults and adolescents (12 years of age and older weighing at least 40 kg):

      • Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and
      • Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination.

      LIMITATIONS OF AUTHORIZED USE

      • PEMGARDA is not authorized for use for treatment of COVID-19, or for post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.
      • PEMGARDA is authorized for use only when the combined national frequency of variants with substantially reduced susceptibility to PEMGARDA is less than or equal to 90% based on available information including variant susceptibility to PEMGARDA and national variant frequencies.
      • Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.
      • In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination.

      PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under state law to prescribe drugs.

      PEMGARDA has been authorized by FDA for the emergency use described above. It is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19.

      PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under Section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb 3(b)(1), unless the authorization is terminated or revoked sooner.

      PEMGARDA is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to any component of PEMGARDA.

      Serious hypersensitivity reactions, including anaphylaxis, and infusion-related reactions can occur during the infusion and up to 24 hours after the infusion of PEMGARDA and may be severe or life threatening. If signs and symptoms of a clinically significant hypersensitivity reaction or infusion-related reaction occur, immediately discontinue administration, and initiate appropriate medications and/or supportive therapy. Permanently discontinue PEMGARDA in individuals who experience signs or symptoms of anaphylaxis.

      PEMGARDA contains polysorbate 80, which is in some COVID-19 vaccines and is structurally similar to polyethylene glycol (PEG), an ingredient in other COVID-19 vaccines. For individuals with a history of severe hypersensitivity reaction to a COVID-19 vaccine, consider consultation with an allergist-immunologist prior to PEMGARDA administration.

      Certain SARS-CoV-2 viral variants may emerge that have substantially reduced susceptibility to PEMGARDA. PEMGARDA may not be effective at preventing COVID-19 caused by these SARS-CoV-2 viral variants. Inform individuals of the increased risk, compared to other variants, for COVID-19 due to SARS-CoV-2 viral variants that exhibit significantly reduced susceptibility to PEMGARDA. If signs and symptoms of COVID-19 occur, advise individuals to test for COVID-19 and seek medical attention, including starting treatment for COVID-19 as appropriate.

      The most common adverse events (all grades, incidence ≥2% and greater than placebo, through Month 6) observed in participants who have moderate-to-severe immune compromise in Cohort A treated with PEMGARDA included systemic and local infusion-related or hypersensitivity reactions, viral infection, upper respiratory tract infection, influenza-like illness, urinary tract infection, fatigue, headache, sinusitis, nasopharyngitis, influenza, and pneumonia.

      The most common adverse events (all grades, incidence ≥2% and greater than placebo, through Month 6) observed in participants who do not have moderate-to-severe immune compromise in Cohort B treated with PEMGARDA included systemic and local infusion-related or hypersensitivity reactions, upper respiratory tract infection, viral infection, influenza-like illness, enterovirus infection, and viral upper respiratory tract infection.

      PEMGARDA should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.

      Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PEMGARDA and any potential adverse effects on the breastfed infant from PEMGARDA.

      The prescribing healthcare provider and/or the provider’s designee is/are responsible for mandatory reporting of all serious adverse events and medication errors potentially related to PEMGARDA within 7 calendar days from the healthcare provider’s awareness of the event. See Section 6.4 of the accompanying Fact Sheet for Healthcare Providers for more information.

      Complete and submit the report online: http://www.fda.gov/medwatch/report.htm. See Section 6.4 of the Fact Sheet for additional mechanisms for reporting.

      See accompanying Fact Sheet for Healthcare Providers and FDA Letter of Authorization.

      1Based on 2/2025 Fact Sheet Veeva record 222-PP-B-US-00070-2